The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Disclosed herein, in certain embodiments, are engineered virus-like particles and compositions that comprise an oligodeoxynucleotide (ODN) for the treatment of a disease or condition. In some embodiments, also disclosed herein are methods of inducing phagocytosis of a target cell and methods of immune modulation.

Provided herein are novel adeno-associated virus (AAV) capsids, compositions (e.g., rAAV) comprising the capsids, and nucleic acids encoding the capsids. Also provided are methods of making and using the capsids and compositions disclosed herein. The rAAV disclosed herein are particularly useful for gene transfer applications where high transduction efficiency is required (e.g., gene therapy).

Provided herein are novel adeno-associated virus (AAV) capsids, compositions (e.g., rAAV) comprising the capsids, and nucleic acids encoding the capsids. Also provided are methods of making and using the capsids and compositions disclosed herein. The rAAV disclosed herein are particularly useful for gene transfer applications where high transduction efficiency is required (e.g., gene therapy).

Nucleic acids encoding fusion proteins that contain an unwanted antigen and a leader sequence for cell secretion are described. Also described are expression cassettes, vectors, cells, and cell lines containing the nucleic acids, as well as methods of using the nucleic acids to treat autoimmune, allergic and other diseases and disorders, such as multiple sclerosis.

Nucleic acids encoding fusion proteins that contain an unwanted antigen and a leader sequence for cell secretion are described. Also described are expression cassettes, vectors, cells, and cell lines containing the nucleic acids, as well as methods of using the nucleic acids to treat autoimmune, allergic and other diseases and disorders, such as multiple sclerosis.

The present invention relates to a fusion protein for enhancing expression efficiency of a target protein. More specifically, the present invention relates to a glutamyl-prolyl-tRNA synthetase from human (hEPRS) WHEP domain (including WHEP domains TRS-1, TRS-2, and TRS-3 which locate at middle sites of the EPRS protein, and linkers connecting the three domains therethrough). When used as a fusion protein for expressing a target protein in E. coli, the hEPRS WHEP domain according to the present invention enhanced water solubility of the target protein.

The present invention relates to a fusion protein for enhancing expression efficiency of a target protein. More specifically, the present invention relates to a glutamyl-prolyl-tRNA synthetase from human (hEPRS) WHEP domain (including WHEP domains TRS-1, TRS-2, and TRS-3 which locate at middle sites of the EPRS protein, and linkers connecting the three domains therethrough). When used as a fusion protein for expressing a target protein in E. coli, the hEPRS WHEP domain according to the present invention enhanced water solubility of the target protein.

A TCR-like antibody or an antigen-binding fragment thereof, the antibody binding to and having specific and improved affinity to an MHC-I molecule, particularly a CMV pp65 peptide complex (CMVP495-503/HLA-A*02:01) presented by HLA-A*02 are disclosed. A nucleic acid for coding the TCR-like antibody or the antigen-binding fragment thereof; an expression vector containing the nucleic acid; a cell transformed to the expression vector; a method for producing same; a composition containing a T cell for expressing the antibody or the antigen-binding fragment thereof as a chimeric antigen receptor; uses of the composition in preventing or treating cancer or an infectious disease; uses of the composition in diagnosis; methods for preventing and/or treating cancer or infectious diseases; and methods for diagnosing are disclosed.

An engineered phage-derived particle (PDP) for expressing a transgene in a target cell transduced with a bacteriophage, the PDP includes (i) less than about 500 bp of DNA from the bacteriophage genome, (ii) an ITR-flanked therapeutic gene up to 20 kb, (iii) an endosomal escape sequence, (iv) a nuclear localization sequence, and (v) a cell-specific targeting moiety. The PDP may escape lysosomal degradation, traffic across the nuclear envelope and expressed a therapeutic gene in a mammalian cell.